Core Insights - The company experienced low double-digit growth for the fifth consecutive quarter, which was a pleasant surprise given the market conditions [2] Market Performance - The company anticipates that the end markets in Q3 will remain consistent with Q2 in terms of buying activity [1] - The pharmaceutical sector is the largest contributor to the company's revenue, accounting for approximately 30% [1]